<DOC>
	<DOCNO>NCT00840684</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , laromustine , daunorubicin , cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose laromustine give together daunorubicin cytarabine treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Laromustine , Daunorubicin , Cytarabine Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine dose laromustine combine daunorubicin hydrochloride cytarabine patient previously untreated acute myeloid leukemia unfavorable cytogenetics . ( Phase I ) - To determine complete remission rate regimen induction therapy . ( Phase II ) Secondary - To determine complete response rate . - To determine safety profile regimen . - To determine overall relapse-free survival . - To evaluate prognostic value molecular marker FLT3 , duplication MLL , Evi-1 . OUTLINE : This multicenter , phase I dose-escalation study laromustine follow phase II study . - Induction treatment : Patients receive laromustine IV day 4 , daunorubicin hydrochloride IV day 1-3 , cytarabine IV continuously day 1-7 . Patients attain complete remission ( CR ) first induction receive second induction treatment comprise daunorubicin hydrochloride IV day 1-3 cytarabine IV twice daily day 1-4 . Patients CR 1 2 induction treatment proceed consolidation treatment . - Consolidation treatment : Patients receive mini-consolidation treatment comprise amsacrine day 1 cytarabine IV twice daily day 1-5 follow 2 course continue consolidation treatment comprise mitoxantrone hydrochloride day 1 2 cytarabine IV 12 hour day 1-5 . - Allogeneic autologous stem cell transplantation : Patients receive busulfan four time daily 4 day melphalan follow allogeneic autologous stem cell transplantation . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) Untreated disease No promyelocytic AML Unfavorable prognosis , define least one following : Cytogenetic abnormality include 5/5q , 7/7q , 3q , 11q23 , ( 6 ; 9 ) , complex abnormality ( ≥ 3 clonal abnormality ) , exclude ( 9 ; 11 ) Baseline hyperleukocytosis ≥ 100 g/L progression leukocytosis extramedullary localization despite treatment hydroxyurea No AML favorable intermediate prognosis No AML secondary myelodysplastic syndrome diagnose within past 3 month myeloproliferative syndrome PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin &lt; 35 μmol/L Transaminases &lt; 2.5 time upper limit normal absence leukemiarelated abnormality Creatinine &lt; 170 μmol/L OR creatinine clearance ≥ 50 mL/min absence leukemiarelated abnormality Not pregnant nursing Normal cardiac function LVEF ( echographic ≥ 40 % isotopic ≥ 50 % ) Affiliated social security system No uncontrolled severe cardiovascular disease , include follow : Myocardial infarction within past 3 month Cardiac insufficiency Uncontrolled arrhythmia No active cancer within past year except basal cell carcinoma skin epithelioma situ cervix No patient deprive freedom guardianship ( include temporary guardianship ) No psychological , familial , geographical , social situation preclude followup No contraindication study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior hydroxyurea allow No concurrent disulfiram No concurrent participation another study experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>